NOVEL SYSTEMIC TREATMENTS FOR ATOPIC DERMATITIS AND CLINICAL TRIAL DESIGN

OCTOBER 2020 | EADV Virtual Congress 2020

PROGRAM CHAIRS

Robert Bissonnette, MD, Montreal, QC, Canada |  Diamant Thaci, MD, Lubeck, Germany |  Thomas Bieber, MD, Bonn, Germany

Welcome and Introduction | Emma Guttman, MD, IEC President, New York, NY, USA

Optimizing Clinical Trial Design for AD drug development | Robert Bissonnette, MD, IEC President Elect, Montreal, QC, Canada 

Novel Systemic Treatments in Pediatrics and Placebo Responses in Systemic Trials | Michael Cork, MD, Sheffield, UK

Monoclonal antibodies targeting Th2 receptors and cytokines (e.g. IL4R, IL-13 and IL-31) | Thomas Bieber, MD, Bonn, Germany

Monoclonal antibodies targeting epithelial-derived protein (e.g. IL-17C, IL-33 and TSLP) | Diamant Thaci, MD, Lubeck, Germany

Monoclonal antibodies with other targets (e.g. OX40, IL-22 and IL-23) and biomarkers of disease response | Emma Guttman, MD, New York, NY, USA

Systemic JAK inhibitors | Eric Simpson, MD, Portland, OR, USA

Topical JAK inhibitors | Jonathan Silverberg, MD, Washington DC, USA